Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity

被引:45
|
作者
Mohamed, Mohamed-Eslam F. [1 ]
Tseng, Tiffany [1 ]
Frye, Reginald E. [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA
关键词
Green tea; EGCG; milk thistle; UGT1A1; estradiol glucuronidation; inhibition; IN-VITRO; UDP-GLUCURONOSYLTRANSFERASE; LIQUID-CHROMATOGRAPHY; DRUG INTERACTIONS; GLUCURONIDATION; ESTRADIOL; PHARMACOKINETICS; CONJUGATION; METABOLISM; RALOXIFENE;
D O I
10.3109/00498254.2010.505669
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Commonly used herbal supplements were screened for their potential to inhibit UGT1A1 activity using human liver microsomes. Extracts screened included ginseng, echinacea, black cohosh, milk thistle, garlic, valerian, saw palmetto, and green tea epigallocatechin gallate (EGCG). Estradiol-3-O-glucuronide (E-3-G) formation was used as the index of UGT1A1 activity. 2. All herbal extracts except garlic showed inhibition of UGT1A1 activity at one or more of the three concentrations tested. A volume per dose index (VDI) was calculated to estimate the volume in which the daily dose should be diluted to obtain an IC50-equivalent concentration. EGCG, echinacea, saw palmetto, and milk thistle had VDI values >2.0L per dose unit, suggesting a higher potential for interaction. 3. Inhibition curves were constructed for EGCG, echinacea, saw palmetto, and milk thistle. IC50 values were (mean +/- SE) 7.8 +/- 0.9, 211.7 +/- 43.5, 55.2 +/- 9.2, and 30.4 +/- 6.9 mu g/ml for EGCG, echinacea, saw palmetto, and milk thistle extracts, respectively. 4. Based on our findings, inhibition of UGT1A1 by milk thistle and EGCG and to a lesser extent by echinacea and saw palmetto is plausible, particularly in the intestine where higher extract concentrations are anticipated. Further clinical studies are warranted.
引用
收藏
页码:663 / 669
页数:7
相关论文
共 50 条
  • [41] Inhibitory Effects of Herbal Extracts on the Activity of Human Sulfotransferase Isoform Sulfotransferase 1A3 (SULT1A3)
    Nagai, Marie
    Fukamachi, Takahiro
    Tsujimoto, Masayuki
    Ogura, Kenichiro
    Hiratsuka, Akira
    Ohtani, Hisakazu
    Hori, Satoko
    Sawada, Yasufumi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (01) : 105 - 109
  • [42] Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecaninduced toxicity in Chinese cancer patients
    Yan, Liang
    Wang, Xiao-fei
    Wei, Lu-man
    Nie, Ya-li
    Liu, Jing-yang
    Zhang, Li-rong
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (03) : 193 - 199
  • [43] UGT1A1*6 AND UGT1A1*27 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE NEUTROPENIA IN JAPANESE PATIENTS WITH NSCLC
    Doi, S.
    Nakamura, Y.
    Fukuda, M.
    Takatani, H.
    Fukuda, M.
    Kinoshita, A.
    Soda, H.
    Oka, M.
    Tsukamoto, K.
    Kohno, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 165 - 165
  • [44] Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project
    Keiko Hikino
    Takeshi Ozeki
    Masaru Koido
    Chikashi Terao
    Yoichiro Kamatani
    Yoshinori Murakami
    Michiaki Kubo
    Taisei Mushiroda
    Journal of Human Genetics, 2019, 64 : 1195 - 1202
  • [45] UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis
    Yang, Yuwei
    Zhou, MengMeng
    Hu, Mingjun
    Cui, Yanjie
    Zhong, Qi
    Liang, Ling
    Huang, Fen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (05) : e479 - e489
  • [46] Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 (FFCD 0504 trial): Final results
    Mitry, E.
    Bouche, O.
    Seitz, J.
    Etienne, P.
    Legoux, J.
    Aparicio, T.
    Breysacher, G.
    Lecaille, C.
    Lecomte, T.
    Jouve, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
    Chen, Yi-Jing
    Hu, Fei
    Li, Chun-Yan
    Fang, Jue-Min
    Chu, Li
    Zhang, Xi
    Xu, Qing
    BIOMARKERS, 2014, 19 (01) : 56 - 62
  • [48] Inhibition of UGT1A1 by natural and synthetic flavonoids
    Liu, Xin-Yu
    Lv, Xia
    Wang, Ping
    Ai, Chun-Zhi
    Zhou, Qi-Hang
    Finel, Moshe
    Fan, Bin
    Cao, Yun-Feng
    Tang, Hui
    Ge, Guang-Bo
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2019, 126 : 653 - 661
  • [49] Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms
    Wenning, L. A.
    Petry, A. S.
    Kost, J. T.
    Jin, B.
    Breidinger, S. A.
    DeLepeleire, I.
    Carlini, E. J.
    Young, S.
    Rushmore, T.
    Wagner, F.
    Lunde, N. M.
    Bieberdorf, F.
    Greenberg, H.
    Stone, J. A.
    Wagner, J. A.
    Iwamoto, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (06) : 623 - 627
  • [50] UGT1A1 polymorphism analysis - The Dartmouth experience
    Chan, D. C.
    Suriawinata, A. A.
    Pipas, J.
    Fadul, C. E.
    Lewis, L. D.
    Yeo, K.
    Tsongalis, G. J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (05): : 661 - 661